New Cognos Performance Solution Helps Pharmaceutical Companies Drive Clinical Trial Success



    Cognos Clinical Trial Enrollment Forecasting Blueprint offers flexible
patient enrollment modeling and analytics, enabling managers to track
enrollment progress, success of costly studies

    PHILADELPHIA, September 11 /CNW/ - Cognos (NASDAQ:   COGN; TSX: CSN), the
world leader in business intelligence and performance management solutions,
continues to extend its pharmaceutical market leadership, announcing today the
launch of a new performance solution designed to help pharmaceutical companies
better anticipate and manage patient enrollment requirements to ensure
clinical trials successfully comply with FDA requirements.

    Clinical trials represent one of the biggest direct-spend components in
most pharmaceutical R&D budgets. Failure to enroll adequate numbers of
patients is a primary reason why some clinical trials fail. The Cognos
Clinical Trial Enrollment Forecasting Blueprint offers the robust forecasting
and enrollment analytics pharmaceutical companies need to help ensure adequate
patient participation in their clinical trials. The Blueprint maximizes
insights into enrollment indicators that can affect the progress of a costly
study, and facilitates collaboration between managers, analysts and individual
investigator sites to make the necessary adjustments that strike the right
balance between cost and performance.

    Using out-of-the-box functionality from Cognos 8 Planning and Cognos 8
Business Intelligence (BI) - including dashboards, analytical reports and a
pre-configured data model - and encompassing pharmaceutical industry best
practices, the Cognos Clinical Trial Enrollment Forecasting Blueprint lets
managers:

    --  Capitalize on an advanced forecasting data model that calculates and
presents for analysis a range of metrics, including planned vs. actual
enrollment windows, site activations, and screen failure percentages

    --  Drill into portfolio reports to undertake more detailed analyses of
trial enrollment and performance, using up-to-date information from multiple
transactional and planning systems

    --  Forecast the impact of 'on-the-fly' changes using 'What if' planning
and scenario analysis. Changes to one enrollment assumption automatically
recalculates all of the impacted data instantly, eliminating the need for
off-line number crunching and facilitating faster decision-making

    --  Easily adjust business rules to best suit current trial management
needs and adapt to sudden changes. New assumptions and rules can be quickly
configured, tested and pushed out to end-users and analysts without requiring
costly developers and complex coding

    --  View the clinical site hierarchy through a powerful workflow
capability that consolidates, in real time, data from the individual
investigator-site level up through regions and countries

    Available immediately to customers, the Cognos Clinical Trial Enrollment
Forecasting Blueprint is the third pharmaceutical solution launched in the
past year. Together with the Cognos Clinical Trial Forecasting Blueprint,
launched in May 2006, the Blueprints enable customers to seamlessly update
financial projections as their enrollment projections evolve, helping them
better understand the cost of changes and the dollar effect of enrollment
projections. The Cognos Sample Optimization Blueprint, also released in May
2006, rounds out current pharmaceutical offerings.

    "Customer-designed or commercial Clinical Trials Management Systems often
lack the flexibility and forecasting capability pharmaceutical companies
require to model the entire enrollment picture across the development
portfolio. Spreadsheets do not offer a viable alternative as they can
introduce substantial control risks and do not incorporate enterprise-class
functionality such as managed workflow, and the ability to push template
changes out to hundreds of users simultaneously," said Bill Stevens, associate
vice president of life sciences at Cognos. "The Cognos Clinical Trial
Enrollment Blueprint offers an approach that eliminates typical concerns of
data integrity and information silos. Managers gain 'right-time' visibility
into the enrollment status of their study portfolio, enabling them to define,
manage and measure critical performance indicators in an efficient and timely
manner."

    Cognos is a recognized leader in delivering performance management
solutions for the pharmaceutical industry. Currently, 25 of the top 30
pharmaceutical firms rely on Cognos performance management software, including
Novartis, Bayer UK, and Quintiles Transnational. For more information about
Cognos solutions for pharmaceuticals and life sciences, please visit
www.cognos.com/lifesciences.

    ABOUT COGNOS PERFORMANCE BLUEPRINTS:

    Cognos offers a full suite of Performance Blueprints to address planning
and performance management process areas that directly impact an
organization's ability to create business value. Both functional and
industry-specific process areas can now be automated, streamlined and
transformed to help organizations quickly create more business value.
Developed by the Cognos Innovation Center for Performance Management, the
Cognos Performance Blueprints are a key component within the Cognos
Performance Management System, which combines technology, best practices,
analytical applications and solutions, and a broad network of partners into a
single performance management solution. For further information on the Cognos
Performance Blueprints see
http://www.cognos.com/innovationcenter/blueprint.html.

    ABOUT COGNOS:

    Cognos, the world leader in business intelligence and performance
management solutions, provides world-class enterprise planning and BI software
and services to help companies plan, understand and manage financial and
operational performance.

    Cognos brings together technology, analytical applications, best
practices, and a broad network of partners to give customers a complete
performance system. The Cognos performance system is an open and adaptive
solution that leverages an organization's ERP, packaged applications, and
database investments. It gives customers the ability to answer the questions
-- How are we doing? Why are we on or off track? What should we do about it? -
and enables them to understand and monitor current performance while planning
future business strategies.

    Cognos serves more than 23,000 customers in more than 135 countries, and
its top 100 enterprise customers consistently outperform market indexes.
Cognos performance management solutions and services are also available from
more than 3,000 worldwide partners and resellers. For more information, visit
the Cognos Web site at http://www.cognos.com.

    Cognos and the Cognos logo are trademarks or registered trademarks of
Cognos Incorporated in the United States and/or other countries. All other
names are trademarks or registered trademarks of their respective companies.
Note to Editors: Copies of previous Cognos press releases and Corporate and
product information are available on the Cognos Web site at www.cognos.com.




For further information:

For further information: Media Contacts: Cognos David DeRosa,
613-738-1338 ext. 3317 david.derosa@cognos.com or For Cognos Lois Paul &
Partners, LLC Melissa Lane, 781-782-5755 Melissa_lane@lpp.com or Investor
Relations: Cognos John Lawlor, 613-738-3503 john.lawlor@cognos.com

Organization Profile

COGNOS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890